NUF2 and tumor prognosis

Abstract

Ren Meng, Yang Lu, Zhao Xiaoting, Yue Wentao. NUF2 and tumor prognosis[J]. Journal of International Oncology, 2022, 49(3): 164-167.

References27

[1]	Ustinov NB, Korshunova AV, Gudimchuk NB. Protein complex NDC80: properties, functions, and possible role in pathophysiology of cell division[J]. Biochemistry (Mosc), 2020, 85(4):448-462. DOI: 10.1134/S0006297920040057. doi:10.1134/S0006297920040057
[2]	Subramonian D, Chen TA, Paolini N, et al. Poly-SUMO-2/3 chain modification of Nuf2 facilitates CENP-E kinetochore localization and chromosome congression during mitosis[J]. Cell Cycle, 2021, 20(9):855-873. DOI: 10.1080/15384101.2021.1907509. doi:10.1080/15384101.2021.1907509
[3]	Uehara DT, Mitsubuchi H, Inazawa J. A missense variant in NUF2, a component of the kinetochore NDC80 complex, causes impaired chromosome segregation and aneuploidy associated with microcephaly and short stature[J]. Hum Genet, 2021, 140(7):1047-1060. DOI: 10.1007/s00439-021-02273-4. doi:10.1007/s00439-021-02273-4
[4]	魏永健, 胡进静, 李汛. CDCA8与肿瘤发生发展及干细胞干性维持的关系[J]. 国际肿瘤学杂志, 2021, 48(4):216-219. DOI: 10.3760/cma.j.cn371439-20201012-00043. doi:10.3760/cma.j.cn371439-20201012-00043
[5]	Jiang X, Jiang Y, Luo S, et al. Correlation of NUF2 overexpression with poorer patient survival in multiple cancers[J]. Cancer Res Treat, 2021, 53(4):944-961. DOI: 10.4143/crt.2020.466. doi:10.4143/crt.2020.466
[6]	Lv S, Xu W, Zhang Y, et al. NUF2 as an anticancer therapeutic target and prognostic factor in breast cancer[J]. Int J Oncol, 2020, 57(6):1358-1367. DOI: 10.3892/ijo.2020.5141. doi:10.3892/ijo.2020.5141
[7]	Wang Y, Tan PY, Handoko YA, et al. NUF2 is a valuable prognostic biomarker to predict early recurrence of hepatocellular carcinoma after surgical resection[J]. Int J Cancer, 2019, 145(3):662-670. DOI: 10.1002/ijc.32134. doi:10.1002/ijc.32134pmid:30653265
[8]	Guo L, Wang Z, Du Y, et al. Random-forest algorithm based biomarkers in predicting prognosis in the patients with hepatocellular carcinoma[J]. Cancer Cell Int, 2020, 20:251. DOI: 10.1186/s12935-020-01274-z. doi:10.1186/s12935-020-01274-z
[9]	Jacobs NR, Norton PA. Role of chromosome 1q copy number variation in hepatocellular carcinoma[J]. World J Hepatol, 2021, 13(6):662-672. DOI: 10.4254/wjh.v13.i6.662. doi:10.4254/wjh.v13.i6.662
[10]	Zhang Y, Tang Y, Guo C, et al. Integrative analysis identifies key mRNA biomarkers for diagnosis, prognosis, and therapeutic targets of HCV-associated hepatocellular carcinoma[J]. Aging (Albany NY), 2021, 13(9):12865-12895. DOI: 10.18632/aging.202957. doi:10.18632/aging.202957
[11]	Xie X, Jiang S, Li X. Nuf2 is a prognostic-related biomarker and correlated with immune infiltrates in hepatocellular carcinoma[J]. Front Oncol, 2021, 11:621373. DOI: 10.3389/fonc.2021.621373. doi:10.3389/fonc.2021.621373
[12]	Cassetta L, Fragkogianni S, Sims AH, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets[J]. Cancer Cell, 2019, 35(4): 588-602. e10. DOI: 10.1016/j.ccell.2019.02.009. doi:S1535-6108(19)30104-7pmid:30930117
[13]	Xing C, Wang Z, Zhu Y, et al. Integrate analysis of the promote function of cell division cycle-associated protein family to pancreatic adenocarcinoma[J]. Int J Med Sci, 2021, 18(3):672-684. DOI: 10.7150/ijms.53243. doi:10.7150/ijms.53243
[14]	Wong CH, Lou UK, Li Y, et al. CircFOXK2 promotes growth and metastasis of pancreatic ductal adenocarcinoma by complexing with RNA-binding proteins and sponging miR-942[J]. Cancer Res, 2020, 80(11):2138-2149. DOI: 10.1158/0008-5472.CAN-19-3268. doi:10.1158/0008-5472.CAN-19-3268pmid:32217695
[15]	Zheng L, Li L, Xie J, et al. Six novel biomarkers for diagnosis and prognosis of esophageal squamous cell carcinoma: validated by scRNA-seq and qPCR[J]. J Cancer, 2021, 12(3):899-911. DOI: 10.7150/jca.50443. doi:10.7150/jca.50443
[16]	Chen M, Li S, Liang Y, et al. Integrative multi-omics analysis of identified NUF2 as a candidate oncogene correlates with poor prognosis and immune infiltration in non-small cell lung cancer[J]. Front Oncol, 2021, 11:656509. DOI: 10.3389/fonc.2021.656509. doi:10.3389/fonc.2021.656509
[17]	Sun ZY, Wang W, Gao H, et al. Potential therapeutic targets of the nuclear division cycle 80 (NDC80) complexes genes in lung adenocarcinoma[J]. J Cancer, 2020, 11(10):2921-2934. DOI: 10.7150/jca.41834. doi:10.7150/jca.41834
[18]	Hitti E, Bakheet T, Al-Souhibani N, et al. Systematic analysis of AU-Rich element expression in cancer reveals common functional clusters regulated by key RNA-binding proteins[J]. Cancer Res, 2016, 76(14):4068-4080. DOI: 10.1158/0008-5472.CAN-15-3110. doi:10.1158/0008-5472.CAN-15-3110
[19]	Xu W, Wang Y, Wang Y, et al. Screening of differentially expressed genes and identification of NUF2 as a prognostic marker in breast cancer[J]. Int J Mol Med, 2019, 44(2):390-404. DOI: 10.3892/ijmm.2019.4239. doi:10.3892/ijmm.2019.4239
[20]	Zhai X, Yang Z, Liu X, et al. Identification of NUF2 and FAM83D as potential biomarkers in triple-negative breast cancer[J]. PeerJ, 2020, 8:e9975. DOI: 10.7717/peerj.9975. doi:10.7717/peerj.9975
[21]	Zhang W, Qiu X, Sun D, et al. Systematic analysis of the clinical relevance of cell division cycle associated family in endometrial carcinoma[J]. J Cancer, 2020, 11(19):5588-5600. DOI: 10.7150/jca.46324. doi:10.7150/jca.46324
[22]	Tang H, Wu Z, Zhang Y, et al. Identification and function analysis of a five-long noncoding RNA prognostic signature for endometrial cancer patients[J]. DNA Cell Biol, 2019, 38(12):1480-1498. DOI: 10.1089/dna.2019.4944. doi:10.1089/dna.2019.4944
[23]	Xie X, Lin J, Fan X, et al. LncRNA CDKN2B-AS1 stabilized by IGF2BP3 drives the malignancy of renal clear cell carcinoma through epigenetically activating NUF2 transcription[J]. Cell Death Dis, 2021, 12(2):201. DOI: 10.1038/s41419-021-03489-y. doi:10.1038/s41419-021-03489-y
[24]	Zhang H, Zou J, Yin Y, et al. Bioinformatic analysis identifies potentially key differentially expressed genes in oncogenesis and progression of clear cell renal cell carcinoma[J]. PeerJ, 2019, 7:e8096. DOI: 10.7717/peerj.8096. doi:10.7717/peerj.8096
[25]	Shan L, Zhu XL, Zhang Y, et al. Expression and clinical significance of NUF2 in kidney renal clear cell carcinoma[J]. Transl Androl Urol, 2021, 10(9):3628-3637. DOI: 10.21037/tau-21-620. doi:10.21037/tau-21-620pmid:34733658
[26]	Tokuzumi A, Fukushima S, Miyashita A, et al. Cell division cycle-associated protein 1 as a new melanoma-associated antigen[J]. J Dermatol, 2016, 43(12):1399-1405. DOI: 10.1111/1346-8138.13436. doi:10.1111/1346-8138.13436
[27]	Huang C, Chen L, Savage SR, et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma[J]. Cancer Cell, 2021, 39(3): 361-379. e16. DOI: 10.1016/j.ccell.2020.12.007. doi:10.1016/j.ccell.2020.12.007pmid:33417831

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References27

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[6]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[7]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[8]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[9]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[10]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[11]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[12]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[13]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[14]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[15]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.